Drug intelligence / Profile preview

BREMEN

Development stage: Unknown
Lead developer: EMS
Modality: Small Molecules
Administration: Ophthalmic

Overview

BREMEN is an investigational fixed-dose combination ophthalmic solution developed by the Brazilian pharmaceutical company EMS for the management of primary open-angle glaucoma and ocular hypertension. It contains brimonidine tartrate, an alpha-2 adrenergic agonist, and timolol maleate, a non-selective beta-adrenergic antagonist. The combination works synergistically to lower intraocular pressure (IOP) by decreasing the production of aqueous humor and increasing uveoscleral outflow. In clinical development, BREMEN was evaluated in a Phase 3 randomized, investigator-masked trial (NCT03235232) to demonstrate therapeutic equivalence in efficacy and safety to the reference product Combigan.

Brand names: BREMEN
Other names: brimonidine tartrate + timolol maleatebrimonidine + timolol

Targets

ADRA2A (α2A)ADRB2 (β2)ADRB1 (β1)

Beyond the preview

Go deeper on BREMEN.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BREMEN.

Explore the full profile